Eukaryotic initiation factor 2B (eIF2B) is the guanine nucleotide exchange factor for eIF2 and a critical regulator of protein synthesis, (e.g., as part of the integrated stress response). Certain mutations in the EIF2B genes cause leukoencephalopathy with vanishing white matter (VWM), an often serious neurological disorder. Comprising 5 subunits, ␣-(eIF2B being the catalytic one), eIF2B has always been considered an ␣␤␥␦ heteropentamer. We have analyzed the subunit interactions within mammalian eIF2B by using a combination of mass spectrometry and in vivo studies of overexpressed complexes to gain further insight into the subunit arrangement of the complex. Our data reveal that eIF2B is actually decameric, a dimer of eIF2B(␤␥␦) tetramers stabilized by 2 copies of eIF2B␣. We also demonstrate a pivotal role for eIF2B␦ in the formation of eIF2B(␤␥␦) tetramers. eIF2B(␣␤␥␦) 2 decamers show greater binding to eIF2 than to eIF2B(␤␥␦) tetramers, which may underlie the increased activity of the former. We examined the levels of eIF2B subunits in a panel of different mouse tissues and identified different levels of eIF2B subunits, particularly eIF2B␣, which implies heterogeneity in the cellular proportions of eIF2B(␣␤␥␦) and eIF2B ( 
during the initiation of mRNA translation. It promotes the exchange of guanosine diphosphate (GDP) bound to eIF2 for guanosine triphosphate (GTP), to generate active eIF2·GTP complexes, which can then bind the initiator methionyl-transfer RNA (Met-tRNA The regulation of the activity of eIF2B is fundamentally important for controlling the initiation of translation (1) . Several mechanisms for controlling eIF2B activity have been identified. The best studied one involves the phosphorylation of eIF2␣ on Ser51, which converts eIF2 from a substrate for eIF2B into a potent competitive inhibitor (2) . In mammals, there are 4 distinct eIF2␣ kinases, which are activated under specific stress conditions, leading to inhibition of eIF2B and thus overall protein synthesis. However, the phosphorylation of eIF2␣ actually causes the up-regulation of the translation of certain mRNAs by virtue of upstream open reading frames (ORFs) in their 5=-leader regions. eIF2B can also be regulated through its own phosphorylation (3) (4) (5) . eIF2B comprises 5 different subunits, ␣-ε. The largest, eIF2Bε, contains the catalytic (GEF) domain near its C terminus (6) . The N-terminal part of eIF2Bε shows sequence similarity to eIF2B␥ (7, 8) . We recently showed that highly conserved residues within the regions of human eIF2B␥ and -ε are crucial for their mutual interaction (9) . eIF2B␣, ␤, and ␦ also show mutual sequence similarity (10) ; in yeast, they form a stable heterotrimeric subcomplex (11) . Also in yeast, eIF2B␣ is not essential, whereas disruption of the genes for eIF2B␤-ε is lethal. Instead, eIF2B␣ confers sensitivity to phosphorylation of eIF2 (12) . In mammalian eIF2B, loss of eIF2B␣ from the eIF2B complex decreases its GEF activity (13) (14) (15) . Furthermore, siRNA-mediated knockdown of eIF2B␣ suppresses the effects of eIF2 phosphorylation caused by vesicular stomatitis virus (16) .
The crucial importance of eIF2B for cellular function is powerfully illustrated by the fact that mutations in genes for eIF2B subunits lead to a neurological disorder, leukoencephalopathy with vanishing white matter [VWM; also termed childhood ataxia with central hypomyelination (CACH); refs. 17, 18] . Patients with VWM exhibit chronic and progressive degenerative symptoms, including ataxia and spasticity. However, episodes of more severe degeneration can occur after head trauma or infection with fever. Depending on the causative mutation, VWM may be very severe, with neonatal onset and death ensuing soon after birth, or it can exhibit a less severe phenotype that manifests later in life (19) . Our previous studies showed that mutations in the genes encoding eIF2B␤-ε (EIF2B2, -3, -4, and -5), which cause VWM, affect the function of human eIF2B in diverse ways (15, 20) . However, to date, there are no data for the effects of VWM mutations in the gene for eIF2B␣ (EIF2B1).
Some VWM mutations affect the interactions between eIF2B subunits within the complex. For example, the Gly329Val mutation in eIF2B␤ leads to dissociation of eIF2B␣ from the complex and reduced eIF2B activity (20) . Two other mutants in eIF2B␤, Gly200Val and Pro291Ser, disrupt the binding of this subunit to other subunits (20) .
In this study, we used mass spectrometry (MS) and complementary biochemical approaches to analyze the subunit composition and organization of human eIF2B. Our data reveal that the eIF2B holocomplex is actually a decamer with ␣ 2 ␤ 2 ␥ 2 ␦ 2 ε 2 stoichiometry. We also demonstrated that decamerization depends on eIF2B␣, which is sufficient and necessary for decamer formation. Human eIF2B complexes lacking eIF2B␣ are heterotetramers and show decreased binding to eIF2, which may explain their lower GEF activity. We reevaluated the effect of the Ala391Asp (A391D) VWM mutation in eIF2B␦, which we had previously demonstrated does not affect the composition or activity of eIF2B(␣␤␥␦ε) complexes, even though it does cause very serious disease (15) . We showed that, in the context of eIF2(␤␥␦ε) complexes, which cannot dimerize, this mutation causes severe adverse effects on the integrity of the eIF2B complex. Finally, we investigated the expression of eIF2B subunits in a panel of mouse tissues, and the results suggest the presence of a heterogeneous population of eIF2B(␣␤␥␦ε) and -(␤␥␦ε) in different tissues.
MATERIALS AND METHODS

Chemicals and reagents
All chemicals used in this study were purchased from SigmaAldrich (Poole, UK), Fisher Scientific (Loughborough, UK), or Melford (Ipswich, UK).
Plasmids
Plasmids encoding N-terminal myc-tagged eIF2B subunits and His 6 /Myc-tagged eIF2Bε and eIF2B ␦ are described elsewhere (9, 15) . His 6 /myc-tagged eIF2B␣ was produced by cloning the coding ORF of eIF2B␣ into the pHM backbone. Plasmids encoding the untagged eIF2B subunits were produced by cloning the relevant ORFs into pcDNA 3.1 (Life Technologies, Paisley, UK). The vector for bacterial expression of eIF2B␣ was produced by cloning the eIF2B␣ ORF into pGEX-6P-1 (GE Life Sciences, Little Chalfont, UK). A vector encoding cleavable GST-tagged eIF2B␦ was produced by cloning into pEBG-6P1 (a gift from Prof. D. Alessi; Medical Research Council Protein Phosphorylation Unit, Dundee, UK). Site-directed mutagenesis was performed with the Quikchange mutagenesis kit (Agilent, Santa Clara, CA, USA), according to the manufacturer's instructions.
Cell culture, transfection, and lysis
HEK293 and HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum and penicillin/streptomycin (all from Life Technologies). Transfections were performed by the calcium phosphate method, with N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES)-buffered saline, and the concentration of each plasmid was optimized to ensure equal expression of each subunit (9, 15, 20) . At 48 h after transfection, the cells were washed twice with phosphate-buffered saline (PBS) and lysed in lysis buffer (20 mM HEPES, pH 7.6, containing 10% v/v glycerol, 50 mM KCl, 50 mM ␤-glycerophosphate, 0.5% v/v Triton X-100, 0.1 mM EDTA, 0.5 mM NaVO 3 , 14.3 mM 2-mercaptoethanol, and 1ϫ protease inhibitor cocktail; Roche, Burgess Hill, UK). The lysates were clarified by centrifugation at 16,000 g for 15 min at 4°C and stored in aliquots at Ϫ80°C.
SDS-PAGE and Western blot analysis
SDS-PAGE and Western blot analysis were performed as described previously (9, 15) . Briefly, samples were resolved on a 12.5% SDS-PAGE gel and transferred onto nitrocellulose membrane by the semidry method with a Trans-Blot turbo (Bio-Rad, Hemel Hempstead, UK). The membranes were blocked in TBS/0.2% (v/v) Tween-20 (TBST) containing 5% (w/v) bovine serum albumin (BSA) and probed with primary antibody diluted in 5% BSA/TBST. Membranes were then washed with TBST and probed with IR-dye-conjugated secondary antibody (Thermo Fisher Scientific, Loughborough, UK). After a further wash with TBST, the membranes were visualized on a LiCor Odyssey scanner with Odyssey software (LiCor, Cambridge, UK). Quantification was performed with the same software, ensuring that the signal intensity was below saturation.
Antibodies against myc-tag (60003-2-Ig), eIF2B␣ (18010-1-AP), and eIF2B␦ (11332-1-AP) were purchased from Proteintech (Manchester, UK); anti-eIF2␣ (2103S) from Cell Signaling Technology (Hitchin, UK); anti-eIF2B␤ (sc-9979) and eIF2B␥ (sc-9980) from Santa Cruz Biotechnology (Insight Biotechnology, Wembley, UK); and anti-eIF2Bε (ab32713) and anti-GAPDH (ab9485) from Abcam (Cambridge, UK).
pton, UK) and cultured in Lurial-Bertani broth. The protein was expressed and the cells were lysed as described previously (21) . Clarified lysates were bound to Fast-flow glutathione resin (GE Life Sciences). The bound resin was washed and treated overnight at 4°C with PreScission protease (20 U/ml resin; GE Life Sciences). The cleaved, eluted eIF2B␣ (now in the supernatant) was further purified (21) .
Gel filtration of recombinant eIF2B␣
Gel filtration of purified recombinant eIF2B␣[WT] and eIF2B␣[V183F] was performed with a Sephadex 200 10/ 300GL column on an Ä kta purifier FPLC system (GE Life Sciences) equilibrated in 20 mM HEPES-KOH (pH 7.6), 10% (v/v) glycerol, 100 mM KCl, 14.3 mM ␤-mercaptoethanol, and 1 mM PMSF. The column was calibrated with gel filtration markers (Bio-Rad).
Lysate preparation and gel filtration of HeLa cell cytoplasm
HeLa cell cytoplasmic lysates for gel filtration were prepared as described above, with the following modifications. After a wash with PBS, the cells were scraped into a microfuge tube with 500 l PBS and centrifuged at 1000 g for 5 min. The cell pellet was resuspended in a 1-pellet volume of lysis buffer (see above) and incubated on ice for 30 min before being clarified by centrifugation as described above. The lysates were filtered with a 0.22-m Spin-X filter (Corning, Amsterdam, The Netherlands).
Gel filtration was performed with a Superose 6 PC 3.2/30 column on an Ä kta purifier FPLC system (GE Life Sciences) equilibrated in 20 mM HEPES-KOH (pH 7.6), 10% (v/v) glycerol, 500 mM KCl, 14.3 mM ␤-mercaptoethanol, and 1 mM PMSF, with modifications to reduce the pre-and postcolumn volumes. Lysate (20 l) was loaded onto the column at a flow rate of 20 l/min. Fractions (29 l) were collected and analyzed by Western blot.
Nickel-NTA affinity chromatography
Nickel-NTA affinity purification of His 6 -tagged proteins was performed as described previously (9, 15) , with some modifications. Typically, 100 -150 g of protein lysate was applied to 10 l of Ni-NTA resin (Qiagen, Manchester, UK) and topped up to 500 l with Ni-NTA pulldown buffer (20 mM HEPES, pH 7.6; 10% v/v glycerol; 0.15% v/v Triton X-100; 50 mM KCl; 0.1 mM EDTA; 25 mM imidazole; 14.3 mM ␤-mercaptoethanol; and 1ϫ protease inhibitor cocktail; Roche). After incubation for 1 h at 4°C, the complexes were washed 3 times with Ni-NTA pulldown buffer and eluted for Western blot analysis in elution buffer (62.5 mM Tris, pH 6.8; 7% w/v SDS; 20% v/v glycerol; 0.1% w/v bromphenol blue; 250 mM imidazole; and 0.7 M 2-mercaptoethanol).
Purification of recombinant eIF2B complexes from HEK293 cells
HEK293 cells were transfected with plasmids encoding untagged eIF2B␣, -␤, -␥, and -ε, and GST-tagged eIF2B␦ and lysed as described above. Typically, sixty 150-mm plates were used per preparation. The pooled lysate was applied to glutathione resin (GE Life Sciences) equilibrated in lysis buffer. After incubation at 4°C for 1 h, the resin was washed 3 times with cell lysis buffer containing 500 mM KCl and once in PreScission buffer (20 mM HEPES, pH 7.6; 10% v/v glycerol; 50 mM KCl; 0.1% v/v Igepal CA-630; 0.1 mM EDTA; 14.3 mM ␤-mercaptoethanol; and 1ϫ protease inhibitors; Roche). The resin was then resuspended in PreScission buffer containing 20 U/ml resin of PreScission protease (GE Life Sciences) and incubated overnight at 4°C. The next day, the resin was sedimented by centrifugation, and the supernatant containing eIF2B was removed. The resin was further washed with PreScission buffer to elute all the complexes. eIF2B was finally purified by cation exchange chromatography on a 1-ml HiTrap SP FF column on an Ä kta purifier FPLC system (GE Life Sciences) equilibrated with buffer B (PreScission buffer without Igepal CA-630 and KCl), and eluted with 250 mM, 450 mM, and 1 M KCl. Purified eIF2B complexes were recovered in the 450 mM KCl eluate.
MS of intact eIF2B protein complexes
For intact MS, proteins were exchanged into 500 mM ammonium acetate (pH 7.4), by using Amicon centrifugal devices (Millipore, Watford, UK). MS and tandem MS spectra were acquired on a high-mass Q-TOF-type instrument (22) adapted for a QSTAR XL platform (AB Sciex, Warrington, UK) (23), using in-house prepared gold-coated glass capillaries (24) . Optimized instrument parameters were ion spray voltage 1.3 kV, declustering potential 100 V, focusing potential 200 V, and collision energy (CE) up to 200 V, MCP 2350 V. For tandem MS, complexes from the relevant mass/charge (m/z) range were selected in the second quadrupole and subjected to acceleration in the collision cell.
Label-free quantitative proteomic analyses eIF2B(␣␤␥␦ε) and eIF2B(␤␥␦ε) were purified from HEK293 cells as above, with the following modifications. Purified proteins were concentrated in a centrifugal concentrator column and exchanged into 100 mM ammonium bicarbonate. The proteins were reduced in 5 mM dithiothreitol for 30 min at 56°C and subsequently alkylated with 25 mM iodoacetamide at room temperature for 20 min. Each protein sample was digested by incubation with 0.5 g of trypsin in 1 l of 100 mM ammonium bicarbonate for 16 h at 37°C. Digested protein samples were lyophilized and resuspended in buffer A (1% v/v acetonitrile containing 0.1% v/v formic acid) containing 20 fmol/l of an enolase digest as an internal standard (Waters, Manchester, UK). Sample (5 l) was loaded onto a reverse-phase trap column (5 m, 300 m ϫ 50 mm; Xbridge BEH C18; Waters) at a trapping rate of 5 l/min and washed for 10 min with buffer A, before the analytical nano-LC separation on a C18 reversed-phase column (1.8 m, 250 mm ϫ 75 m; HSS T3 C18; Waters). The eluted peptides were fractionated over a 37-min linear gradient from 1% acetonitrile and 0.1% formic acid, up to 80% acetonitrile plus 0.1% formic acid, at a flow rate of 300 nl/min. Eluted samples were sprayed directly into a Synapt G2-S HDMS mass spectrometer (Waters), operating in MS e mode with ion mobility separation enabled. Data were acquired from 50 to 1990 m/z, with alternate low and high CE scans, where the low CE was set to 5 V, and the elevated CE was ramped from 20 to 40 V. The lock mass Glu-fibrinopeptide [(Mϩ2H) ϩ2 , m/zϭ785.8426] was infused at a concentration of 100 fmol/l with a flow rate of 250 nl/min and acquired every 13 s.
The raw mass spectra were submitted to ProteinLynx Global Server 3.0 (Waters), and the data were processed to generate reduced-charge state and deisotoped precursor and associated product ion mass lists. These mass lists were searched against the human UniProt protein sequence database (July 2013; http://www.uniprot.org) concatenated with the enolase protein sequence. A maximum of 1 missed cleavage and a fixed modification for the carboxyamidom-ethylation of cysteine were allowed. The oxidation of methionine and deamidation of glutamine and asparagine were set as variable modifications.
Preparation of lysates from mouse tissue
Tissues were harvested from freshly euthanized wild-type (WT) C57/Bl6 mice and frozen at Ϫ80°C. Approximately 10 mg of tissue was minced with a scalpel and suspended in 500 l of ice-cold RIPA buffer (50 mM Tris, pH 7.5; 10% v/v glycerol; 50 mM KCl, 1% v/v Triton X-100; 0.5% w/v sodium deoxycholate; 0.1% w/v SDS; 0.5 mM EDTA; 0.5 mM EGTA; 14.3 mM ␤-mercaptoethanol; and 1ϫ protease inhibitors; Roche). The lysates were homogenized and incubated at 4°C for 2 h with rotation and then sonicated on ice for 3 min (1 s sonication and 2 s pause at 15% power on a Sonoplus sonicator; Bandelin, Berlin, Germany) and cleared by centrifugation at 16,000 g for 30 min at 4°C. Protein concentrations were determined by the Bradford method, and lysates were stored at Ϫ80°C.
Multiple sequence alignment
Protein sequences for eIF2B␣, -␤, and -␦ from Homo sapiens, Mus musculus, Rattus norvegicus, Danio rerio, Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae were obtained from the University of California-Santa Cruz (UCSC; Santa Cruz, CA, USA) genome browser (http:// genome.ucsc.edu). The sequences were aligned with ClustalW (25) and visualized with Jalview (26).
Homology modeling
Homology models for human eIF2B␦ were obtained from the Modbase server (http://modbase.compbio.ucsf.edu).
RESULTS
MS of eIF2B reveals that it is heterodecamer
To obtain information about the higher-order interactions between the eIF2B subunits, we used tandem MS of purified eIF2B to identify the complexes and subcomplexes that are present in solution. This approach can provide valuable information regarding the intersubunit contacts within the complex. eIF2B(␣␤␥␦ε) complexes were expressed in HEK293 cells and purified by affinity and ion exchange chromatography. Complexes were then exchanged with 500 mM ammonium acetate (pH 7.4) and subjected to MS. Spectra were interpreted on the basis of the predicted molecular masses of the individual subunits (Fig. 1A) . The spectrum of the eIF2B(␣␤␥␦ε) complex showed that several species were present in solution ( Table 1) . As judged by peak intensity, the 3 major complexes were eIF2B(␣␤␦␥ε) heterodecamers and eIF2B(␤␥␦ε) tetramers, with 2:2:2:2:2 and 1:1:1:1 stoichiometry, respectively, and eIF2B␣ homodimers. We also observed small amounts of eIF2B(␣␤␥␦ε) nonamers, lacking 1 copy of eIF2Bε, and eIF2B␣ monomers. Interestingly, we did not observe eIF2B(␣␤␥␦ε) pentamers, except after application of CE to eIF2B(␣␤␥␦ε) decamers, suggesting that such complexes are not a natural state for eIF2B and that the decameric form of eIF2B-(␣␤␥␦ε) is the native state for this complex.
Further insights into subunit interactions within eIF2B were obtained by isolating ions corresponding to particular complexes in the mass spectrometer and applying CE to disrupt interactions between eIF2B subunits. MS data for dissociated subunits and corresponding stripped complexes (Table 1) revealed that the ␣ and ␤ subunits dissociate most readily from the eIF2B decamer. However, eIF2B␥ and eIF2Bε can also be stripped from the complex at high CE. Notably, all the complexes identified by MS at high CEs that contained more than 1 copy of eIF2B␤, -␥, -␦ and/or -ε also contained Ն1 copy of eIF2B␣. This result suggests that eIF2B␣ mediates the dimerization of 2 eIF2B-(␤␥␦ε) tetramers. We did not observe free eIF2B␦ in any spectra, whereas the other individual subunits were detected, most likely because of the difference in Figure 1 . Native MS of human eIF2B complexes expressed in HEK293 cells. A) SDS-PAGE and mass spectrum of the purified recombinant eIF2B(␣␤␥␦ε) complex showing the main species at 9000 -12000 m/z (gray stars), corresponding in mass to the decamer of the eIF2B comprising 2 of each subunit. Additional species are present corresponding in mass to the ␣ subunit (black circles) at 2500 -3500 m/z, a-dimer (two black circles) at 3500 -5500 m/z, eIF2B(␤␥␦ε) tetramer (gray diamonds) at 6500 -8000 m/z, and eIF2B decamer lacking 1 ε subunit (black diamonds) at 9000 m/z. B) SDS-PAGE and mass spectrum of the purified recombinant eIF2B(␤␥␦ε) complex showing the main species at 6000 -7000 m/z (gray diamonds), which corresponds in mass to the eIF2B(␤␥␦ε) heterotetramer. In addition, species corresponding in mass to the eIF2B(␥ε) dimer (black diamonds) at 4500 -5000 m/z and the eIF2B(␤␥␦) trimer (gray squares) at 5000 -5500 m/z were present, as were individual subunits eIF2B␤ (black circles) and eIF2B␥ (gray circles) at 2750 -3500 m/z. theoretical pI of this subunit (pIϭ9.45) compared with that of the other subunits (pI range 4.97-6.91), leading to a positive charge of eIF2B␦ at pH 7.4, whereas the other subunits are negatively charged. Therefore, this subunit is not drawn into the MS.
We repeated the experiment with purified eIF2B(␤␥␦ε) complexes, to further probe the stoichiometry and arrangement of the eIF2B subunits. MS analysis of this complex confirmed its tetrameric stoichiometry ( Fig. 1B and Table 1 ) and demonstrated the existence of eIF2B(␥ε) catalytic subcomplexes with 1:1 stoichiometry. Applying high CE to disrupt the eIF2B(␤␥␦ε) tetramer resulted in dissociation of the ␤ and ε subunits from the tetrameric complex while retaining the interactions between the remaining subunits, as evidenced by the presence of eIF2B(␤␥␦) and eIF2B(␦␥ε) complexes. Furthermore, complexes containing eIF2B␤ and eIF2B␥ε without eIF2B␦ are not observed in the MS data, suggesting an important role for eIF2B␦ in the contacts between eIF2B␤ and the eIF2B(␥ε) subcomplex. In this regard, eIF2B␦ can be considered the core subunit for assembly of eIF2B(␤␥␦ε) tetramers.
The MS data demonstrated that eIF2B is a heterodecamer, comprising a dimer of eIF2B(␤␥␦ε) tetramers stabilized by eIF2B␣. It was therefore of considerable interest that the MS analysis showed that eIF2B␣ dimers occur in solution, since dimerization of this subunit may mediate dimerization of the whole complex.
eIF2B␣ dimerizes in vitro and in vivo
To further examine the eIF2B␣ homodimers observed in the MS data, we first examined its crystal structure (21) . It showed homodimerization of eIF2B␣ via the Rossmann fold-like domains toward the C terminus of the subunit (Fig. 2A) . This arrangement has also been observed in several sequence and structural homologues, including the archaeal homologue aIF2B␣ (pdb:1T9K) and ribose 5-phosphate isomerase (pdb: 2YRF), both of which possess a similar monomeric structure containing a helical bundle and Rossmann fold. Both homodimerize via the Rossmann fold domain in a manner similar to that observed in the eIF2B␣ structure.
To investigate whether eIF2B␣ can dimerize in solution (i.e., that its dimerization is not an artifact of crystallization or MS), we expressed it in E. coli, purified it, and analyzed the resulting material by size-exclusion chromatography (Fig. 2B ). eIF2B␣ eluted with an apparent molecular mass of ϳ68 kDa, twice that expected for the 34-kDa monomer, indicating that this subunit does indeed dimerize.
To assess whether eIF2B␣ dimerizes in mammalian cells, we expressed two different versions of eIF2B␣ in HEK293 cells: one with an N-terminal myc-tag and one with N-terminal 6xHis (His 6 ) and myc-tags. His 6 -tagged proteins were isolated on Ni-NTA agarose. If dimerization of eIF2B␣ occurs, both the His 6 -myc and myc-tagged versions of the protein would be recovered, whereas without dimerization, only the His 6 -myc tagged protein would be detected by Western blot (Fig. 2C) . Both forms of the protein were retained on the Ni-NTA resin, whereas the myc-only tagged protein was not bound when expressed alone. This result confirms that overexpressed eIF2B␣ dimerizes in human cells (Fig. 2D) .
Of note, one of the few reported VWM mutations in 
472,860 472,577.53
484,110 486,085.31 Ϯ 55.38
489,388 491,707.72 Ϯ 120.
523,100 525,464.69 Ϯ 69.64
eIF2B(␣␤␥␦⑀) and -(␤␥␦⑀) were analyzed by tandem MS of intact complexes. Complexes identified in the first quadrupole are labeled solution. Calculated and measured masses of each identified complex are shown, as are the parent complexes of the collision complexes.
eIF2B␣, which leads to the amino acid change Val183Phe (V183F), occurs at the eIF2B␣ dimerization interface indicated in Fig. 2A. eIF2B␣ [V183F] did not dimerize when expressed in E. coli ( Fig. 2B ; the recombinant eIF2B␣[V183F] protein runs at the expected monomeric size of 34 kDa). The same behavior was observed in human cells (Fig. 2D) , consistent with the notion that eIF2B␣ dimerization does involve the interface depicted in Fig. 2A .
To assess the dimerization of endogenous eIF2B␣, we prepared cytoplasmic lysates from HeLa cells, which have been shown to contain an excess of free eIF2B␣ (27) . We resolved these on a Superose 6 gel filtration column and probed for eIF2B␣ (Fig. 2E) . To confirm accurately the molecular weight of endogenous eIF2B␣, we also analyzed HeLa lysates spiked with recombinant WT or V183F eIF2B␣ (Fig.  2E ). These data revealed that endogenous eIF2B␣ resolves at the same molecular mass as the recombinant WT eIF2B␣, distinct from the V183F eIF2B␣, confirming that it dimerizes.
The eIF2B holocomplex dimerizes in an eIF2B␣-dependent manner
Having confirmed the formation of homodimers of endogenous eIF2B␣, we sought to confirm the existence of eIF2B(␣␤␥␦ε) decamers in human cells. We used an approach similar to that used to investigate dimerization of eIF2B␣ (Fig. 2C) , but in this case, with His 6 -myc tagged eIF2Bε and myc-tagged versions of all 5 subunits. Decamer formation would be indicated by copurification of the myc-tagged eIF2Bε with His 6 -myctagged eIF2Bε and the other eIF2B subunits. We investigated eIF2B(␣␤␥␦ε),eIF2B(␤␥␦ε), and eIF2B(␥ε), the 3 eIF2B complexes that can be purified from mammalian cells (20) . After affinity purification on Ni-NTA agarose, we observed copurification of myc-eIF2Bε and therefore decamerization of the complex, but only when eIF2B␣ was coexpressed (Fig. 3A) . This finding confirms that eIF2B decamerization depends on eIF2B␣, consistent with the MS data. Since the MS data demonstrated that eIF2B complexes containing eIF2B␣ could exist only as decameric complexes and not the The recently published crystal structure of human eIF2B␣ (pdb:3ECS; ref. 21) suggests that the monomers interact through the C-terminal Rossmann fold domain to form a dimer, in a manner similar to that of interactions identified in sequence and structural homologues. A VWM mutation, Val183Phe (V183F), has been identified in eIF2B␣ and is located within the intersubunit interface. B) WT and V183F-mutant human eIF2B␣ were expressed in E. coli and purified and analyzed by size-exclusion chromatography on a Superdex 200 10/300 GL column, calibrated with molecular mass standards. C) Approach used for investigating dimerization of eIF2B␣ overexpressed in HEK293 cells by coexpression of His 6 -myc-and myc-eIF2B␣. Affinity purification and Western blot analysis would show dimerization if both forms were present after the pulldown. D) His6/myc-tagged and myc-tagged eIF2B␣ were expressed in HEK293 cells, either separately or in combination, and in vivo dimerization was tested by subjecting cell lysates to affinity chromatography ion Ni-NTA beads and analyzing the bound proteins by SDS-PAGE/Western blot with anti-myc. Their migration positions are indicated. E) Size-exclusion chromatography of HeLa cell cytoplasm shows that endogenous free eIF2B␣ resolves as a dimer. Unspiked lysate was compared to lysate spiked with recombinant WT and V183F eIF2B␣, to show the resolving positions of dimeric and monomeric eIF2B␣, respectively. pentameric complexes previously described for eIF2B in human cells, we assumed that all the eIF2B␣-containing complexes were decameric.
Having demonstrated that overexpressed eIF2B(␣␤␥␦ε) is present as a decamer, it was important to establish whether such complexes occur with endogenous eIF2B. To this end, we used size-exclusion chromatography of HeLa cell cytoplasm samples to examine the size of native eIF2B complexes. We resolved the column with a buffer containing 500 mM KCl, to dissociate the inter- Figure 3 . eIF2B dimerizes in an eIF2B␣-dependent manner. A) Various combinations of myc-tagged eIF2B subunits ␣-ε and His6/myc-tagged eIF2Bε were coexpressed in HEK293 cells as indicated. Lysates were subjected to affinity chromatography on Ni-NTA agarose, and the bound material was analyzed by Western blot, to test dimerization, as described in the text. Myc-eIF2Bε was copurified only in complexes comprising all 5 eIF2B subunits. However, eIF2B(␤␥␦ε) and eIF2B(␥ε), which lack eIF2B␣, did not dimerize. B) HeLa cell cytoplasm was separated by size-exclusion chromatography on a Superose 6 column, and fractions were analyzed by Western blot. C) Affinity pulldowns of eIF2B(␣␤␥␦ε) and eIF2B(␤␥␦ε) (similar to those in (A) were reprobed for eIF2␣ and phospho-eIF2␣(Ser51) by Western blot analysis. The levels of eIF2␣ were quantified and normalized to the level of eIF2B␤, to give a measure of the amount of eIF2 bound per half of the dimer (nϭ5; error bars are sem). See Table 2 for quantitative proteomic analysis of semipurified eIF2B complexes. D) Myc-tagged eIF2B subunits and His6/myc-tagged eIF2Bε were overexpressed in HEK293 cells. Lysates for cells that did not overexpress myc-eIF2B␣ were combined with increasing amounts of recombinant eIF2B␣ and subjected to Ni-NTA affinity pulldown and Western blot for myc-tag, eIF2B␣ and eIF2␣. Increasing levels of eIF2B␣ led to increased dimerization of eIF2B and increased binding of eIF2. Quantification of the data shows a linear increase in eIF2B decamer formation (measured by myc-eIF2Bε coelution) and eIF2␣ binding with addition of increased recombinant eIF2B␣. E) Dimerization of eIF2B␣ is not necessary for dimerization of eIF2B. The experiment detailed in A was repeated with lysates expressing WT and V183F eIF2B␣.
action between eIF2B and eIF2, which would have clouded our interpretation. Western blot analysis of fractions for eIF2B␦, to represent the tetrameric eIF2B(␤␥␦ε) complex, and eIF2B␣ showed that complexes containing both these subunits eluted at a predicted molecular mass of ϳ750 kDa (Fig. 3B) , consistent with previous data (28) for semipurified eIF2B. By reprobing the membranes for eIF2␣, we confirmed that the size of the complex was not due to the presence of eIF2, noting that it resolved separately from the eIF2B subunits. Interestingly, the eIF2B␦ signal used to detect the other subunits in the complex was spread broadly in the fractions, whereas the eIF2B␣ signal was strongest in the high-M r complexes, perhaps because of its presence within either decameric eIF2B(␣␤␥␦ε) or tetrameric eIF2B(␤␥␦ε) complexes in the cytoplasm, leading to peak broadening. To test this broadening, we repeated the experiment with purified eIF2B(␣␤␥␦ε) and eIF2B(␤␥␦ε) complexes. Of note, whereas the eIF2B(␤␥␦ε) complex resolved as a single peak at ϳ250 kDa, in agreement with previous findings (14) , eIF2B(␣␤␥␦ε) again showed broadening of the eIF2B␦ signal, spreading between the fractions containing complexes with eIF2B␣ and the fractions containing the eIF2B(␤␥␦ε) tetramers (Fig. 3B) . Furthermore, we found a large excess of free eIF2B␣ eluting later from the column at the size of eIF2B␣ homodimers. From these data, we suggest that the interaction of eIF2B␣ with the rest of the complex is not as strong as other subunit interactions, as also suggested by the MS data, and that it can readily dissociate from the rest of the eIF2B complex. We have shown in several previous studies that eIF2B(␤␥␦ε) complexes show less than 50% of the GEF activity of the eIF2B(␣␤␥␦ε) complexes (13) (14) (15) , whereas others have shown that eIF2B(␤␥␦ε) complexes are insensitive to inhibition by eIF2 phosphorylated on Ser51 of eIF2␣ (16, 29) . We investigated whether changes in the association of eIF2 with the different eIF2B complexes might be a contributing factor to this decrease in activity by reprobing of the Western blots of the pulled-down material for eIF2␣ and found that, in the absence of eIF2B␣, a lower amount of eIF2 binds to eIF2B complexes. Normalizing the amount of eIF2 to that of eIF2B␤, to represent the amount of eIF2 bound to each half of the decamer, revealed a consistent 50% decrease in the binding of eIF2 to the complex in the absence of eIF2B␣ (Fig. 3C) , which suggests that the dimerization of eIF2B complexes enhances their catalytic efficiency. Western blot analysis with a phosphospecific antibody revealed that the level of binding of eIF2 phosphorylated at Ser51 in its ␣ subunit decreased in proportion to the drop in total eIF2 binding (Fig. 3C) , indicating that the reduced binding of eIF2 is not due to the reduced affinity of eIF2B(␤␥␦ε), as compared to eIF2B(␣␤␥␦ε), for phosphorylated eIF2 that has been extensively reported (12, 16) .
To complement these studies, we also used a quantitative proteomic approach to assess the degree of association of eIF2 with eIF2B(␣␤␥␦ε) or eIF2B(␤␥␦ε) complexes. Complexes were expressed in HEK293 cells with GST-tagged eIF2B␦ and untagged versions of the other subunits, purified on glutathione beads under low-salt conditions to retain eIF2B:eIF2 interactions, cleaved from the resin and subjected to tryptic digestion followed by MS analysis. The data reveal that the molar ratio of eIF2␣␤␥ to -␤␥ε (eIF2B␦ was excluded from the analysis since, as the tagged subunit, it was present in a higher proportion in the eluate) present in the pulldowns was 0.211 for eIF2B(␣␤␥␦ε) complexes and 0.1291 for eIF2B(␤␥␦ε) complexes ( Table 2) . These data therefore show that eIF2B(␤␥␦ε) complexes have reduced binding of eIF2 to ϳ60% of that observed for eIF2B(␣␤␥␦ε) complexes, in broad agreement with the data in Fig. 3C .
To investigate whether eIF2B␣ itself can drive formation of eIF2B(␣␤␥␦ε) decamers, we performed Ni-NTA pulldowns of eIF2B as in Fig. 3A , adding increasing amounts of recombinant eIF2B␣ to the eIF2B(␤␥␦ε) pulldown lysates during the incubation with the resin. We found that addition of increasing amounts of recombinant eIF2B␣ led to a proportional increase in eIF2B dimerization, as measured by the increasing intensity of the myc-eIF2Bε band, and in the binding of eIF2 to the complex (Fig. 3D) . This finding indicates that eIF2B␣ alone is both necessary and sufficient to drive decamer formation.
The data described above are consistent with the conclusion that the dimerization of eIF2B is mediated through the dimeric interface of eIF2B␣ ( Fig. 2A) , since eIF2B␣ is necessary for the dimerization of the complex, and adding back eIF2B␣ is sufficient to drive dimerization. To test this possibility, we overexpressed eIF2B complexes with WT eIF2B␣ or eIF2B␣[V183F], Quantitative proteomic analysis of semipurified eIF2B shows reduced molar association of eIF2 with eIF2B(␤␥␦⑀). GST-tagged eIF2B was purified under low-salt conditions and analyzed by quantitative proteomics, as described in Materials and Methods, to give absolute quantification of eIF2B and eIF2 subunits. The mean amount of eIF2 was compared to the mean amount of eIF2B(␤␥⑀) (since eIF2B␦ was the tagged subunit, and was overrepresented in the pulldown). eIF2B(␤␥␦⑀) was found to pull down 60% of the level of eIF2 pulled down by eIF2B(␣␤␥␦⑀), confirming the reduced association observed by Western blot (see Fig. 3 ). which fails to undergo dimerization (Fig. 2B, D) , and performed Ni-NTA resin pulldowns as before. Surprisingly, disruption of the dimeric interface failed to prevent dimerization of the overall complex eIF2B (Fig.  3E) , indicating that dimerization of eIF2B␣ is not necessary for decamer formation and consistent with the MS data that show the presence of complexes that contain 2 copies of eIF2B␤, -␥, -␦, and -ε, but only 1 of eIF2B␣ (Table 1 ). The likely explanation for this is multiple contacts between eIF2B␣ and the rest of the complex, allowing one eIF2B␣ protein to contact both tetramers in the decamer, thereby mediating dimerization of the eIF2B(␤␥␦ε) complexes (discussed below and depicted in the models in Fig. 6A ).
Other VWM mutants and eIF2B dimerization
The regulatory eIF2B subunits (␣␤␦) display a high level of mutual sequence homology. Given that eIF2B␣[V183F] cannot dimerize, we asked whether any other VWM mutations occur at residues in the corresponding regions of the eIF2B␤ and eIF2B␦ subunits. A multiple sequence alignment of eIF2B␣, -␤, and -␦ showed a high level of homology between them, particularly in the region of the Rossmann fold. This sequence alignment also revealed that Val183 corresponds to Ala391 in eIF2B␦ (Fig. 4A) . Mapping of this residue onto a homology model of eIF2B␦ confirmed that it resides in a location similar to that of Val183 of eIF2B␣ (Fig. 4B ). This location is the site of the eIF2B␦[Ala391Asp(A391D)] VWM mutation, which results in the most severe phenotype of VWM, including effects on other organs, including the pancreas, lens, and ovaries. However, we have shown that this mutation has little if any effect on eIF2B complex formation or activity when coexpressed with the other 4 eIF2B subunits (15) .
We performed Ni-NTA pulldowns of eIF2B subunits overexpressed in HEK293 cells with WT or A391D myc-eIF2B␦, in the presence and absence of coexpressed eIF2B␣. As expected, in the presence of eIF2B␣, the heterodecameric eIF2B holocomplex was observed (Fig. 4C) . However, in the absence of eIF2B␣, the association of eIF2B␤ and eIF2B␦ with eIF2B␥ε was greatly diminished (Fig. 4C) , which suggests that eIF2B␣ suppresses the effect of the eIF2B␦ A391D mutant and, consequently, that this mutation may produce the most striking effect in cells and tissues with low levels of eIF2B␣. Interestingly, other VWM mutants that affect additional tissues commonly impair the integrity of eIF2B complexes (15, 30) .
Expression of eIF2B␣ in different tissues
One implication of the essential role of eIF2B␣ in the formation of eIF2B decamers is that eIF2B could exist as a mixture of tetrameric eIF2B(␤␥␦ε) and decameric eIF2B(␣␤␥␦ε), their proportion being determined by the relative levels of expression of eIF2B␣. Furthermore, the eIF2B␦[A391D] mutation would affect only showed that A391 is in a location similar to that of V183 in eIF2B␣ in their respective proteins. C) Myctagged eIF2B␣, -␤, and -␥ subunits and His6/myctagged eIF2Bε were expressed in HEK293 cells, together with either WT or A391D myc-eIF2B␦, as indicated. Ni-NTA affinity purification of the complexes was performed, followed by SDS-PAGE/immunoblot analysis with anti-myc antibody.
the integrity of the eIF2B complexes in cells in which eIF2B␣ expression is substoichiometric. Therefore, we determined the expression of the different eIF2B subunits in a panel of mouse tissues by Western blot analysis (Fig. 5A) . The data were quantified and normalized to the median expression level for each subunit across the tissues, to bring the data for each subunit into a similar range (Fig. 5B) . We observed differences in the levels of the eIF2B subunits, with the highest overall level of eIF2B observed in testis, the most proliferative tissue tested, in agreement with mRNA expression observed in a prior study (10) . Of note, we observed the greatest variation between different tissues for eIF2Bε, with strikingly high levels in heart compared to that in the other subunits and increased levels of eIF2Bε in relation to those of other subunits in the brain tissues (hippocampus, cerebral cortex, and cerebellum) and the kidney. The relative proportions of eIF2B␤, -␥, and -␦ remained fairly similar throughout the different tissues. Interestingly, we observed some variation in eIF2B␣ levels compared with those of the other subunits. In particular, eIF2B␣ levels in the ovary were relatively lower than those of the other subunits compared to those in other tissues, which would correspond to our observations for the eIF2B␦[A391D] mutation in Fig. 4 , suggesting that the eIF2B␦ [A391D] mutant is able to manifest only in tumors with relatively lower levels of eIF2B␣, leading to an increased proportion of eIF2B(␤␥␦ε) in these tissues. It is important to note that, although these data allow us to observe differences in the levels of eIF2B subunits between tissues and differences in the relative levels of the subunits within tissues, they do not give us absolute levels of each subunit. We are, therefore, unable to comment on the proportion of eIF2B(␣␤␥␦ε) to eIF2B(␤␥␦ε) complexes in each tissue, save to say that the proportion of the latter is expected to be greater in tissues with lower relative levels of eIF2B␣, such as the ovary.
DISCUSSION
eIF2B is more complicated than most GEFs, which are monomeric proteins. It has been known for Ͼ2 decades that eIF2B comprises 5 different subunits, based initially on the work of Hinnebusch and colleagues (31) . Pavitt and colleagues (11) made the important observation that the ␥ and ε subunits of yeast eIF2B form a catalytic subcomplex, whereas eIF2B␣, -␤, and -␦ create a regulatory subcomplex. However, little else is known about the arrangement of these subunits.
We have now studied the structural arrangement of eIF2B subunits. Such information is important to understanding how the structural arrangement of the subunits contributes to the function and regulation of this complex and how VWM mutations can affect these parameters. We used 3 complementary approaches: MS analysis of intact eIF2B complexes; expression of combinations of eIF2B subunits in mammalian cells, followed by isolation and Western blot analysis of the resulting complexes; and size-exclusion chromatography of cytoplasmic lysates. These techniques consistently showed that human eIF2B exists as the heterodecamer ␣ 2 ␤ 2 ␥ 2 ␦ 2 ε 2 . Furthermore, we showed that eIF2B␣ is necessary for formation of this decameric structure, so that complexes lacking this subunit are ␤␥␦ε tetramers.
MS analysis of eIF2B(␣␤␥␦ε) complexes demonstrated that they form decamers containing 2 ␤␥␦ε tetramers whose interaction is stabilized by the presence of 2 copies of eIF2B␣. They do not form eIF2B(␣␤␥␦ε) pentamers. The MS data ( Fig. 1 and Table 1 ) imply that the tetramers associate in the presence of eIF2B␣ (since, in the absence of eIF2B␣, only single copies of other subunits are ever observed). These data are supported by analysis of complexes ectopically expressed in human cells and isolated by affinity chromatography, which showed that eIF2B forms decamers only in the presence of eIF2B␣ (Fig. 3) . Our data also showed that eIF2B␣ forms homodimers (Fig. 2) , consistent with the arrangement observed in the crystal structure (21) . This dimerization is disrupted by the VWM mutation V183F. However, the observation from the MS data that complexes containing the eIF2B␣[V183F] mutant are decamers suggests that the dimerization of eIF2B␣ is not necessary for decamer formation. As discussed earlier, the simplest explanation of this apparent paradox is that each ␣-subunit contacts components of both tetramers within the overall eIF2B decamer, as depicted in Fig. 6A . This interaction explains the occurrence of complexes such as eIF2B(␣␤ 2 ␥ 2 ␦ 2 ε 2 ) and certain others listed in Table 1 .
The MS data suggest a pivotal role of eIF2B␦ in mediating interactions within the tetrameric eIF2B(␤␥␦ε) complex. MS spectra at high CE demonstrated that eIF2B␦ is necessary for the interaction of eIF2B␤ with the eIF2B(␥ε) catalytic subcomplex, since larger complexes containing these components were only observed when eIF2B␦ were present ( Table 1) .
The depictions of the overall arrangement of human eIF2B subunits within the decamer (Fig. 6A) are simple working models based on our observations and earlier work with yeast, showing the formation of the eIF2B␥ε and eIF2B␣␤␦ subcomplexes (11) . Thus, our models take into account the following findings: eIF2B␣ can form dimers, but its dimerization is not needed for decamer formation; eIF2B␣ is necessary for the formation of dimerization of eIF2B(␤␥␦ε) tetramers, but only 1 copy of eIF2B␣ is needed to bridge both eIF2B(␤␥␦ε) tetramers; and eIF2B(␤␥␦ε) forms a tetrameric complex with eIF2B␦ at its core. All the observed complexes in the MS data can be explained by this model. The inverted conformation of the model in Fig. 6Aii takes into account the observation that residues in eIF2B␤ are necessary for tight eIF2 binding in yeast (32) . We hypothesize that in this model, eIF2B␤ may assist binding of eIF2 to the catalytic subunit on the other half of the complex.
Although mammalian eIF2B␣ must be present for the formation of eIF2B decamers, it appears to dissociate quite readily from the other subunits, as judged from our consistent ability to isolate tetrameric eIF2B(␤␥␦ε) complexes from rabbit or human cells (13) (14) (15) . Our MS data support this, showing that eIF2B␣ dissociated at a lower CE than other subunits ( Fig. 1 and Table 1 ). Furthermore, eIF2B␣ readily dissociated from purified eIF2B(␣␤␥␦ε) complexes on size-exclusion chromatography (Fig. 3B) . Notably, eIF2B␣ has been shown to have other interaction partners, suggesting that it may have additional cellular functions aside from its role in eIF2B (33) . Furthermore, the different ratios of eIF2B␣ to the other eIF2B subunits in different tissues suggests that eIF2B is present in cells as the decameric eIF2B(␣␤␥␦ε) and tetrameric eIF2B(␤␥␦ε) species, supported by the isolation of both eIF2B(␣␤␥␦ε) and eIF2B(␤␥␦ε) complexes from cell lysates (13) (14) (15) .
That the eIF2B␦[A391D] mutation, which displays no defects on complex formation or activity when expressed together with the other 4 subunits (15) , is located at a position equivalent to eIF2B␣(V183F) prompted us to further investigate its possible effects on eIF2B in the context of decamer formation. We showed that in the absence of eIF2B␣, eIF2B␦[A391D] is less able to form complexes with eIF2B␤, -␥, and -ε than is WT eIF2B␦ (Fig. 4C) . Thus, the presence of eIF2B␣ nullifies the deleterious effects of this mutation in the core subunit, eIF2B␦. Given that this and other mutations (e.g., eIF2B␦[R483W], eIF2B␤[G200V], and eIF2B␤[P291S]; ref. 30 ) that affect multiple tissues also influence complex formation, it is possible that, in some tissues where relatively lower levels of eIF2B␣ are available to associate with other eIF2B subunits, defects in eIF2B function arise when eIF2B␦, for example, is mutated in this way. Indeed, we observe differing levels of expression of eIF2B subunits in different tissues (Fig.  5) , supporting the likely existence of heterogeneous populations of eIF2B(␣␤␥␦ε) 2 decamers and eIF2B(␤␥␦ε) tetramers. In particular, we observed reduced relative levels of eIF2B␣ in ovary, one of the tissues also affected by such VWM mutations as eIF2B␦[A391D], which is likely to be the reason that this mutation manifests a pathogenic effect in that tissue.
Our observations lead us to propose a model that incorporates both the importance of eIF2B decamer formation and the heterogeneity of eIF2B complex populations in different tissues (Fig. 6B) . We have previously shown that eIF2B(␤␥␦ε) has lower GEF activity than eIF2B(␣␤␥␦ε) (13) (14) (15) , and we suggest that this reduced activity is due to lesser binding of eIF2 to eIF2B(␤␥␦ε) than to eIF2B(␣␤␥␦ε) (although we cannot discriminate between decamerization and the presence of eIF2B␣ per se in accounting for this effect). Furthermore, it is well established that eIF2B␣ is necessary to confer sensitivity of the eIF2B complex to inhibition by eIF2 phosphorylated on Ser51 of eIF2␣ in response to cell stress (12, 16) . Finally, as discussed above, the levels of different eIF2B subunits in the cell suggest a heterogeneous population of eIF2B complexes. Thus, we propose that the level of eIF2B␣ controls the ratio of eIF2B(␣␤␥␦ε) to eIF2B(␤␥␦ε) in cells. Cells with a higher ratio of eIF2B␣ to the other eIF2B subunits (as depicted in Fig. 6B, left panel) are expected to have an increased population of eIF2B(␣␤␥␦ε) decamers with a higher GEF activity, but with the caveat that they can be more readily inhibited by phosphorylated eIF2. Cells with a lower proportion of eIF2B␣ have a reduced number of eIF2B(␣␤␥␦ε) decamers than eIF2B(␤␥␦ε) tetramers and an overall lower level of eIF2B activity, but are resistant to inhibition by phosphorylated eIF2. Differences in the ratios of the 2 eIF2B complexes may reflect different functions of the tissues. For example, we observed a slight increase in the level of eIF2B␣ in the hippocampus compared with that in other brain tissues. Since phosphorylation of eIF2 is involved in the development of long-term memory (34) , that this increase in relative eIF2B levels may reflect this function. A role for eIF2B␣ levels in proliferation is supported by the observation that this transcript is upregulated by the c-myc oncogene, a driver of cell proliferation (34) . Fine-tuning of eIF2B␣ levels in individual cells within a tissue may also reflect cell function and merits further study.
Our findings demonstrate for the first time that mammalian eIF2B is a decameric protein, reveal the key role of eIF2B␣ in decamer formation, and provide new insights into the overall organization of the eIF2B complex. They also provide important clues to the molecular basis of the pathologic effects of VWM mutations and tissue-specific tuning of the eIF2B complex population and responses to cell stress that are mediated through eIF2 phosphorylation.
